We observed in preclinical models of MM that AT-101, by disrupting Bcl-2 and Mcl-1 function, potentiates the cytotoxic effects of lenalidomide (Revlimid) and dexamethasone (Rd) [21]. This evidence concerns the gene BCL2 and Miyoshi myopathy.